Navigation Links
Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Date:5/3/2012

SHELTON, Conn. and SEOUL, Korea, May 3, 2012 /PRNewswire/ -- Cara Therapeutics, Inc. and Chong Kun Dang Pharmaceutical Corporation (CKD Pharm) today announced that they have entered into a licensing agreement that provides CKD Pharm with the exclusive rights to develop and market Cara's lead analgesic drug candidate, CR845, in the Republic of Korea.  Under the terms of the agreement, Cara will receive an up-front payment, including an equity investment, and is eligible to receive further milestone payments related to pre-defined clinical and regulatory events in Korea and the U.S., as well as royalties on Korean sales of any marketed products containing CR845.

CR845 is a highly selective, peptide-based, peripherally-restricted kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain.  Cara is developing an intravenous formulation of CR845 in the U.S. for the treatment of acute post-operative pain. The Company recently completed a 200-patient Phase II trial with data expected in Q2, 2012.  Earlier this year, Cara successfully completed a Phase I trial with an oral capsule formulation of CR845 which demonstrated a mean oral bioavailability of 16% across all patient groups and peripheral kappa opioid receptor activation at all doses tested as measured by a standard biomarker.

"CKD Pharm's excellence in clinical development, marketing, and sales in South Korea makes them an ideal partner for the commercialization of CR845 within this territory," said Derek Chalmers, CEO of Cara Therapeutics. "As we continue to advance both the IV and oral formulations of CR845 in the U.S., this transaction will allow Cara to expand its clinical and commercial activities into this growing marketplace."

CKD Pharm vice chairman, Jung-Woo Kim, Ph.D., commented, "We expect Cara's innovative CR845 compound to be successfully developed under our partnership and be subsequently well positioned to perform in the Korean market in the near future."

About CR845
In a previous randomized, placebo-controlled Phase II study, CR845 demonstrated evidence of analgesic efficacy when administered as a single intravenous dose to women following laparoscopic hysterectomy.  In addition to decreases in reported pain levels, patients receiving CR845 required substantially lower amounts of post-operative opioids (narcotics) and showed a significant reduction in the incidence of post-operative nausea and vomiting. A multicenter, double-blind, randomized, placebo-controlled 200-patient Phase II trial to evaluate the efficacy and safety of intravenous CR845 when administered both pre and post-operatively in women undergoing laparoscopic hysterectomy has completed enrollment, with data expected in Q2, 2012.

About Cara Therapeutics
Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's pipeline includes near-term clinical drug candidates identified as mechanistically distinct, peripherally-acting analgesics.

About Chong Kun Dang Pharm Corp
CKD Pharm, headquartered in Seoul, and employing over 1400 people in Sales and Marketing, Production, and R&D, is one of Korea's leading pharmaceutical companies, with 2011 revenues of over $390 million. In addition to analgesics, CKD markets ethical products in the cardiovascular, anti-infective, and gastrointestinal disease therapeutic areas, among others. The Company is engaged in the development, manufacture, distribution, import and export of pharmaceutical finished products, raw materials, as well as medical devices, among others. CKD's core products include remedies for high blood pressure and high cholesterol, immunosuppressive drugs, analgesics and remedies for cold. It also produces antitumor agents, antibiotics, digestives, circulation agents, respiratory agents, remedies for endocrine diseases, remedies for skin diseases, and others.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Cara's expectations. Factors that could cause actual results to differ materially from the forward-looking statements may include, but are not limited to, the timing, success and cost of Cara's research and clinical studies and Cara's ability to obtain additional financing. These forward-looking statements represent Cara's judgment as of the date of this release. Cara disclaims any intent or obligation to update these forward-looking statements.

www.ckdpharm.com


'/>"/>
SOURCE Cara Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , Feb. 20, 2017 Systems ... that creates detailed images of the organs and tissues ... field and radio waves. The technique does not use ... of brain function or growth of cancer. MRI is ... neurology, cardiology, oncology, musculoskeletal, and orthopedics. Hence, MRI helps ...
(Date:2/20/2017)... -- Report analyzes the worldwide markets for Infusion ... Ambulatory Infusion Pumps, Enteral Feeding Pumps, Insulin Infusion ... and Syringe Infusion Pumps. The report provides separate ... Asia-Pacific, Latin America, and Rest of World. ... Annual estimates and forecasts are provided for ...
(Date:2/20/2017)... This report analyzes the worldwide markets for Human ... comprehensive analytics for the US, Canada , ... Asia-Pacific , and Rest of World. ... Annual estimates and forecasts are provided for the period ... for these markets. Market data and analytics are derived from ...
Breaking Medicine Technology:
(Date:2/20/2017)... Fla. (PRWEB) , ... February 20, 2017 , ... Scrubbing ... Cancer Center in Houston, Dr. Christopher Pezzi remembers the excitement of the surgeon training ... believe they pay us to do this? Don’t tell anyone, but I would do ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... industries, announced Biscom Document Router (BDR), the first IoT device from Biscom designed ... and imaging. Biscom will debut BDR at HIMSS17 and will be ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's Hospital celebrated a ... out ceremony on Friday marked the halfway point of construction and lifting of the ... 2018, will serve as a center for innovation aimed at finding new discoveries and ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be participating as an ... event will take place February 23-25, 2017 at the Calvin L. Rampton Salt Palace ... with three new ambulances on display. , “JEMS is a leader ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... disruptive innovation in the industry, according to the recent NEJM Catalyst Insights Report ... surveys of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, ...
Breaking Medicine News(10 mins):